# Pizarra — PT-pseudo_3ceacc9b660b (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3ceacc9b660b
Task: 1

Encounter: Urology - outpatient on 23 Feb 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 58-year-old male
  - PSA: 6.0 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.13 ng/mL²
  - PSA velocity: 0.34 ng/mL/yr
  - Prior PSA: 5.4 ng/mL
  - Prostate volume: 49.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7948016 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: amlodipine, lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 6 ng/mL. PI-RADS 3. PSAD 0.13. Prostate volume 49 mL. csPCa 0.79.

Vitals: weight 60 kg, height 178 cm, BMI 18.9, BP 125/74 mmHg, HR 70 bpm. Smoking: Non-smoker.

Chief complaint: Persistent elevation of prostate-specific antigen combined with prior histological confirmation of low-grade malignancy necessitates clinical reassessment.

History: Mr. X is a 58-year-old retired mechanical engineer who lives in a multi-generational home with his spouse and adult daughter. A non-smoker, he maintains an alcohol-free lifestyle and performs chair-based exercises to accommodate limited mobility. Urinary complaints are minimal, scoring 2 out of 35 on the IPSS. His medical background includes hypertension, currently managed with amlodipine, lisinopril, and metoprolol. Additional historical points feature a stable HbA1c of 6.4%, a remote appendectomy during his thirties, and a recent vascular surgery consultation for varicose veins, with no accompanying systemic complaints or bone pain.

Physical examination: DRE: The prostate exhibits a symmetric enlargement characterized by a smooth, firm consistency. Palpation identifies no nodules or asymmetrical areas. General survey shows stable vital signs, an unremarkable abdominal exam, and no palpable lymphadenopathy.

Patient info: retired mechanical engineer; Married; Lives with adult child (multi-generational household).
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Limited mobility — chair-based exercises only; IPSS score: 2/35 (mild LUTS).

Recent other appointments: Vascular surgery — varicose veins consult.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.45 +/- 0.20   (95% CI 0.07-0.84)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.20  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.99 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy or deferral, as the initial panel is insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the context that the patient has a prior positive biopsy, which fundamentally changes the question from "does he have cancer?" to "is the current finding progression or recurrence?" Specifically, the prior did not weigh the specific PI-RADS 3 score against the rising PSA velocity (0.34 ng/mL/yr) or the prior positive biopsy status.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.45 +/- 0.20. This suggestion could be wrong because the classifier's high aleatoric uncertainty (H=0.99) indicates the model cannot distinguish between biopsy and no biopsy based on the input. Furthermore, the prior failed to account for the guideline criterion that states the decision must depend on retrieved documents like the prior grade and MRI comparison, which the prior explicitly ignored.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
The guideline search indicates that the decision hinges on whether the prior grade is documented, whether the lesion changed against a previous MRI, and whether surveillance re-biopsy is due.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_3ceacc9b660b", "radiology_report": "Erasmus MC University Medical Center | 15 Feb 2025 | Multiparametric MRI Prostate\n\nClinical context involves an elevated PSA reading of 6.0 alongside a previously positive biopsy and a PI-RADS 3 designation on earlier imaging.\n\nProstate dimensions total 49.0 mL. T2 sequences highlight a 12 mm hypointense focus within the right mid-gland peripheral zone. Diffusion-weighted sequences exhibit moderately restricted diffusion paired with low ADC values, falling short of definitive malignancy. Contrast-enhanced phases reveal early, equivocal uptake in the lesion. Seminal vesicles appear normal; extracapsular extension and suspicious lymphadenopathy are absent.\n\nPI-RADS 3. PSAD 0.13. csPCa predicted probability 0.7948016."}
get_psa_trend
{"case_id": "PT-pseudo_3ceacc9b660b", "psa_trend": [{"date": "Dec 2023", "val": 1.2}, {"date": "Apr 2024", "val": 2.1}, {"date": "Sep 2024", "val": 3.5}, {"date": "Feb 2025", "val": 6.0}]}
get_previous_notes
{"case_id": "PT-pseudo_3ceacc9b660b", "previous_notes": [{"date": "26 Oct 2024", "author": "Dr. R. van den Berg (GP)", "text": "26 Oct 2024 - Dr. R. van den Berg (GP): PSA climbed to 5.4 ng/mL after a plateau, triggering a urology referral for re-assessment given the earlier positive biopsy. Urinary symptoms remain absent, and routine laboratory panels stay within acceptable ranges."}, {"date": "29 Feb 2024", "author": "Dr. R. van den Berg (GP)", "text": "29 Feb 2024 - Dr. R. van den Berg (GP): A PSA measurement of 4.8 ng/mL indicated a slight quarterly decline. Lower urinary tract symptoms are absent, and the antihypertensive medication course continues without adverse effects."}]}
NOT RETRIEVED
laboratory_results
Left closed because the moderator's agenda did not explicitly require the full lab panel, and the retrieved documents provided sufficient context regarding PSA trajectory and imaging findings.
WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- PSA velocity is positive: 0.34 ng/mL/yr.
- MRI shows a 12 mm hypointense focus with moderately restricted diffusion, suggesting potential concern despite PI-RADS 3.
AGAINST Sampling this patient now:
- Prior biopsy result is documented (though grade is not explicitly stated).
- DRE findings are Normal.
- Previous notes indicate no active surveillance protocol or immediate treatment plan is specified.
WHERE THIS LEANS
The rising PSA trend and the presence of a focal lesion on MRI suggest that further tissue characterization is warranted to resolve the uncertainty stemming from the prior positive biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, showing a rising PSA trend and an equivocal finding on MRI despite the prior positive biopsy, supports the lean towards biopsy.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the context that the patient has a prior positive biopsy, which fundamentally changes the question from "does he have cancer?" to "is the current finding progression or recurrence?" Specifically, the prior did not weigh the specific PI-RADS 3 score against the rising PSA velocity (0.34 ng/mL/yr) or the prior positive biopsy status.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.45 +/- 0.20. This suggestion could be wrong because the classifier's high aleatoric uncertainty (H=0.99) indicates the model cannot distinguish between biopsy and no biopsy based on the input. Furthermore, the prior failed to account for the guideline criterion that states the decision must depend on retrieved documents like the prior grade and MRI comparison, which the prior explicitly ignored.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
The guideline search indicates that the decision hinges on whether the prior grade is documented, whether the lesion changed against a previous MRI, and whether surveillance re-biopsy is due.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Erasmus MC University Medical Center | 15 Feb 2025 | Multiparametric MRI Prostate
The MRI shows a 12 mm hypointense focus within the right mid-gland peripheral zone with moderately restricted diffusion, falling short of definitive malignancy. Extracapsular extension and suspicious lymphadenopathy are absent. PI-RADS 3.

get_psa_trend
[{"date": "Dec 2023", "val": 1.2}, {"date": "Apr 2024", "val": 2.1}, {"date": "Sep 2024", "val": 3.5}, {"date": "Feb 2025", "val": 6.0}]

get_previous_notes
26 Oct 2024 - Dr. R. van den Berg (GP): PSA climbed to 5.4 ng/mL after a plateau, triggering a urology referral for re-assessment given the earlier positive biopsy. Urinary symptoms remain absent, and routine laboratory panels stay within acceptable ranges.
29 Feb 2024 - Dr. R. van den Berg (GP): A PSA measurement of 4.8 ng/mL indicated a slight quarterly decline. Lower urinary tract symptoms are absent, and the antihypertensive medication course continues without adverse effects.

NOT RETRIEVED
laboratory_results
Left closed because the moderator's agenda did not explicitly require the full lab panel, and the retrieved documents provided sufficient context regarding PSA trajectory and imaging findings.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- PSA velocity is positive: 0.34 ng/mL/yr (calculated from 5.4 ng/mL to 6.0 ng/mL over ~4 months).
- MRI shows a 12 mm hypointense focus with moderately restricted diffusion, suggesting potential concern despite PI-RADS 3.
AGAINST Sampling this patient now:
- Prior biopsy result is documented (though grade is not explicitly stated).
- DRE findings are Normal.
- Previous notes indicate no active surveillance protocol or immediate treatment plan is specified.

WHERE THIS LEANS
The rising PSA trend and the presence of a focal lesion on MRI suggest that further tissue characterization is warranted to resolve the uncertainty stemming from the prior positive biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The evidence strongly leans towards biopsy due to rising PSA velocity and an equivocal finding on MRI, despite the prior positive biopsy. The disagreement remains about the final decision based on the interpretation of this evidence versus the guideline criterion.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The conference split between deferral and biopsy, with the evidence leaning towards biopsy due to the rising PSA velocity (0.34 ng/mL/yr) and the presence of a focal lesion on MRI despite the prior positive biopsy. The statistical prior suggested no biopsy, but the retrieved evidence, specifically the PSA trend and MRI findings, overturned this by suggesting further tissue characterization is warranted to resolve the uncertainty stemming from the prior diagnosis.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
